+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection

Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection

Expert Opinion on Investigational Drugs 8(8): 1147-1155

The expanding range of drug options for the management of persons with HIV infection and concerns about the long-term safety of some treatment approaches has precipitated the HIV treatment community to examine a wider range of treatment approaches. One new therapeutic approach is to consider using three nucleoside analogue reverse transcriptase inhibitors, particularly as initial therapy. Recent data comparing triple nucleoside analogue therapy with established 'standard of care' triple therapy regimens have demonstrated similar antiviral effects and tolerability for such regimens. Efficacy and tolerability of triple nucleoside therapy has been demonstrated up to 96 weeks of therapy. This approach has advantages over conventional two nucleoside plus either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor in terms of drug interactions and maintenance of multiple class options. It creates regimens which are, for the most part, compact, twice daily and non-food dependent. Specifically, this approach has already become widely established for individuals for whom drug interactions exclude the use of protease or non-nucleoside antiretrovirals. Triple nucleoside analogue therapy is likely to represent an attractive option for both physicians and patients; its use in clinical practice is likely to further expand.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 050856691

Download citation: RISBibTeXText

PMID: 15992141

DOI: 10.1517/13543784.8.8.1147

Related references

The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. HIV Clinical Trials 1(1): 27-35, 2001

Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. Aids 15(2): 275-277, 2001

Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World Journal of Gastroenterology 20(28): 9486-9496, 2014

Triple drug therapy versus select use of dual nucleoside analogs as front line antiretroviral treatment A cost comparison. Journal of Investigative Medicine 46(1): 100A, 1998

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clinical Infectious Diseases 40(5): 728-734, 2005

Dual nucleoside analogue treatment in the era of highly active antiretroviral therapy (HAART): a single-centre cross-sectional survey. Journal of Antimicrobial ChemoTherapy 48(2): 299-302, 2001

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet. Infectious Diseases 14(7): 572-580, 2014

New approaches to using antiretroviral therapy for the management of HIV Infection. Annals of PharmacoTherapy 31(2): 228-236, 1997

Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. Hospital Practice 27(Suppl. 2): 14-25, 1992

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Expert Opinion on Investigational Drugs 13(1): 55-68, 2004

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated. HIV Clinical Trials 9(6): 387-398, 2009

Lactic acidosis secondary to nucleoside analogue antiretroviral therapy. Aids Reader 10(10): 602-606, 2000

Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. Journal of Acquired Immune Deficiency Syndromes 36(2): 693-701, 2004

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Current Medical Research and Opinion 20(7): 1103-1114, 2004

Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. Journal of the International Aids Society 7(2): 70, 2005